Lack of in vitro–in vivo correlation for a UC781-releasing vaginal ring in macaques

Drug Delivery and Translational Research

Volumn 5, Issue 1, 2015, Pages 27-37

  McConville, Christopher ^a,f   Smith, James M ^b   McCoy, Clare F ^a   Srinivasan, Priya ^b   Mitchell, James ^b   Holder, Angela ^b   Otten, Ron A ^c   Butera, Salvatore ^d   Doncel, Gustavo F ^e   Friend, David R ^e   Malcolm, R Karl ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Antiretroviral; HIV microbicide; In vivo in vitro correlation; UC781; Vaginal ring

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; SILASTIC; ANILIDE; CYTOKINE; FURAN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL MICELLE CONCENTRATION; CRYSTAL STRUCTURE; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MACACA; NONHUMAN; PRIORITY JOURNAL; VAGINA FLORA; VAGINA RING; VAGINAL SECRETION; VIRUS TRANSMISSION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; FEMALE CONTRACEPTIVE DEVICE; METABOLISM; SOLUBILITY; VAGINA;

ANILIDES; ANIMALS; CONTRACEPTIVE DEVICES, FEMALE; CYTOKINES; DRUG LIBERATION; FEMALE; FURANS; MACACA; REVERSE TRANSCRIPTASE INHIBITORS; SOLUBILITY; VAGINA;

EID: 84921930923     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0216-4     Document Type: Article

References (36)

1. Beyrer C, Karim Abdool Q. The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS. 2013;8:306–10.
2. Ferguson LM, Rohan LC. The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Ther Deliv. 2011;2:1535–50.
3. Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antivir Res. 2013;99:391–400.
4. Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012;12:289.
5. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Aids. 1998;12:1129–38.
6. Buckheit Jr RW, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch LA, Roberson J, et al. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retrovir. 1997;13:789–96.
7. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol. 1997;71:3023–30.
8. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. Aids. 2003;17:653–61.
9. Borkow G, Salomon H, Wainberg MA, Parniak MA. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retrovir. 2002;18:711–4.
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.
11. Clark MR, Johnson TJ, McCabe RT, Clark JT, Tuitupou A, Elgendy H, et al. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci. 2012;101:576–87.
12. Fetherston SM, Geer L, Veazey RS, Goldman L, Murphy DJ, Ketas TJ, et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother. 2013;68:394–403.
13. Fetherston SM, Malcolm RK, Woolfson AD. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Ther Deliv. 2010;1:785–802.
14. Gunawardana M, Moss JA, Smith TJ, Kennedy S, Kopin E, Nguyen C, et al. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J Med Microbiol. 2011;60:828–37.
15. Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother. 2012;56:1291–9.
16. Malcolm K, Woolfson D, Russell J, Andrews C. In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. J Control Release. 2003;91:355–64.
17. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antivir Res. 2010;88:S30–9.
18. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. Vaginal rings for delivery of HIV microbicides. Int J Womens Health. 2012;4:595–605.
19. Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother. 2012;56:2251–8.
20. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56:954–6.
21. Moss JA, Baum MM, Malone AM, Kennedy S, Kopin E, Nguyen C, et al. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. Aids. 2012;26:707–10.
22. Moss JA, Malone AM, Smith TJ, Butkyavichene I, Cortez C, Gilman J, et al. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother. 2012;56:5952–60.
23. Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012;56:875–82.
24. Promadej-Lanier NJ, Smith M, Srinivasan P, McCoy CF, Butera S, Woolfson AD, et al. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J Med Primatol. 2009;38:263–71.
25. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A. 2010;110:16145–50.
26. Thurman AR, Clark MR, Hurlburt JA, Doncel GF. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health. 2013;5:695–708.
27. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006;325:82–9.
28. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279–81.
29. Sivin I, Mishell Jr DR, Alvarez F, Brache V, Elomaa K, Lahteenmaki P, et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception. 2005;71:122–9.
30. Purslow C. Researchers announce launch of latest HIV microbicide trial. Expert Rev Clin Pharmacol. 2012;5:497.
31. Mc Conville C, Major I, Friend DR, Clark MR, Woolfson AD, Malcolm RK. Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. J Biomed Mater Res B Appl Biomater. 2012;100:891–5.
32. Academies NRC ot N. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC; 2010
33. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception. 2007;76:348–56.
34. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell Jr DC. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause. 2008;15:94–7.
35. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–9.
36. Patton DL, Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, Parniak MA, et al. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother. 2007;51:1608–15.